Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16707071 | 0.82 | TRPV4 (0.44) | TRPV4 | |
| SCHEMBL16707070 | 0.80 | — | — | |
| SCHEMBL16707074 | 0.80 | — | — | |
| SCHEMBL13021579 | 0.75 | TRPV4 (0.40) | CYP1A2CYP3A4CYP2C19TRPV4ALDH1A1 | |
| SCHEMBL13863736 | 0.75 | TRPV4 (0.54) | CYP1A2CYP3A4CYP2C19TRPV4 | |
| SCHEMBL16707069 | 0.75 | — | — | |
| SCHEMBL16707073 | 0.72 | FFAR4 (0.36) | CYP3A4 | |
| SCHEMBL20393224 | 0.72 | LMNA (0.42) | CYP1A2CYP3A4CYP2C19POLBKMT2A | |
| SCHEMBL14075237 | 0.71 | TRPV4 (0.45) | TRPV4ALDH1A1POLBKMT2AKDM4E | |
| SCHEMBL20257119 | 0.69 | CYP4F2 (0.39) | CYP3A4TRPV4KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862887-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-20150129800-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150129800-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | CCND2, CFD, CRY1 | CYP1A2 2707/4885CYP3A4 2372/4885CYP2C19 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.